Effect of autologous stem cell transplantation on multiple myeloma in the era of targeted novel agents
10.3760/cma.j.issn.1009-9921.2014.11.003
- VernacularTitle:靶向新药时代自体造血干细胞移植在多发性骨髓瘤治疗中的作用
- Author:
Fang BAO
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Autologous stem cell transplantation;
Thalidomide;
Lenalidomide;
Bortezomib
- From:
Journal of Leukemia & Lymphoma
2014;23(11):654-657,663
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is malignant plasma cell clonal disease.Autologous stem cell transplantation (ASCT) strengthen the advantages of the high-dose chemotherapy in treatment of MM,which achieves long-term survival in some patients.Even in the era of targeted novel agents,ASCT can still obviously increase the response rate of treatment.To improve the therapeutic efficacy,targeted novel agents were administrated before and after ASCT.However,targeted novel agents still cannot replace ASCT therapy in the treatment of MM.The direction of future research is to find more reasonable,effective and low toxic treatment.
